1.27 USD
+0.01 (+0.79%)
1.26 USD
-0.01 (-0.79%)
Overall SSKN gets a fundamental rating of 1 out of 10. We evaluated SSKN against 186 industry peers in the Health Care Equipment & Supplies industry. SSKN may be in some trouble as it scores bad on both profitability and health. SSKN has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
SSKN had negative earnings in the past year.
In the past year SSKN has reported a negative cash flow from operations.
SSKN had negative earnings in each of the past 5 years.
In multiple years SSKN reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of SSKN (-35.94%) is worse than 61.29% of its industry peers.
SSKN has a worse Return On Equity (-840.18%) than 83.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.94% | ||
| ROE | -840.18% | ||
| ROIC | N/A |
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SSKN has a Gross Margin (57.76%) which is in line with its industry peers.
SSKN's Gross Margin has declined in the last couple of years.
SSKN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.76% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
2. Health
2.1 Basic Checks
SSKN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SSKN has more shares outstanding
Compared to 5 years ago, SSKN has less shares outstanding
Compared to 1 year ago, SSKN has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -11.16, we must say that SSKN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SSKN (-11.16) is worse than 79.03% of its industry peers.
A Debt/Equity ratio of 10.22 is on the high side and indicates that SSKN has dependencies on debt financing.
The Debt to Equity ratio of SSKN (10.22) is worse than 86.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.16 |
ROIC/WACCN/A
WACC12.12%
2.3 Liquidity
SSKN has a Current Ratio of 0.95. This is a bad value and indicates that SSKN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.95, SSKN is not doing good in the industry: 86.56% of the companies in the same industry are doing better.
A Quick Ratio of 0.75 indicates that SSKN may have some problems paying its short term obligations.
SSKN has a Quick ratio of 0.75. This is amonst the worse of the industry: SSKN underperforms 84.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.75 |
3. Growth
3.1 Past
The earnings per share for SSKN have decreased by -0.38% in the last year.
The Revenue has decreased by -5.19% in the past year.
The Revenue has been growing slightly by 1.22% on average over the past years.
EPS 1Y (TTM)-0.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.08%
Revenue 1Y (TTM)-5.19%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-21.23%
3.2 Future
SSKN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.14% yearly.
Based on estimates for the next years, SSKN will show a small growth in Revenue. The Revenue will grow by 2.23% on average per year.
EPS Next Y29.66%
EPS Next 2Y21.43%
EPS Next 3Y17.14%
EPS Next 5YN/A
Revenue Next Year-9.3%
Revenue Next 2Y-1.15%
Revenue Next 3Y2.23%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SSKN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SSKN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SSKN's earnings are expected to grow with 17.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.43%
EPS Next 3Y17.14%
5. Dividend
5.1 Amount
No dividends for SSKN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.27
+0.01 (+0.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners19.58%
Inst Owner Change-4.6%
Ins Owners0.18%
Ins Owner Change-0.24%
Market Cap7.48M
Revenue(TTM)30.98M
Net Income(TTM)-11.04M
Analysts85
Price Target7.55 (494.49%)
Short Float %6.12%
Short Ratio0.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.02%
Min EPS beat(2)-104.6%
Max EPS beat(2)8.56%
EPS beat(4)1
Avg EPS beat(4)-94.34%
Min EPS beat(4)-271.14%
Max EPS beat(4)8.56%
EPS beat(8)2
Avg EPS beat(8)-98.86%
EPS beat(12)4
Avg EPS beat(12)-57.78%
EPS beat(16)7
Avg EPS beat(16)-39.57%
Revenue beat(2)0
Avg Revenue beat(2)-14.84%
Min Revenue beat(2)-17.42%
Max Revenue beat(2)-12.25%
Revenue beat(4)1
Avg Revenue beat(4)-8.34%
Min Revenue beat(4)-17.42%
Max Revenue beat(4)4.61%
Revenue beat(8)3
Avg Revenue beat(8)-8.04%
Revenue beat(12)4
Avg Revenue beat(12)-5.63%
Revenue beat(16)6
Avg Revenue beat(16)-2.84%
PT rev (1m)-7.5%
PT rev (3m)-7.5%
EPS NQ rev (1m)-33.74%
EPS NQ rev (3m)-33.74%
EPS NY rev (1m)-13.01%
EPS NY rev (3m)-13.01%
Revenue NQ rev (1m)-5.53%
Revenue NQ rev (3m)-8.51%
Revenue NY rev (1m)-8.07%
Revenue NY rev (3m)-8.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.24 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.69 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.67
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS5.26
BVpS0.22
TBVpS-0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.94% | ||
| ROE | -840.18% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.76% | ||
| FCFM | N/A |
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
F-Score3
Asset Turnover1.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 38.81% | ||
| Cap/Sales | 5.36% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.75 | ||
| Altman-Z | -11.16 |
F-Score3
WACC12.12%
ROIC/WACCN/A
Cap/Depr(3y)63.47%
Cap/Depr(5y)69.64%
Cap/Sales(3y)9.91%
Cap/Sales(5y)10.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.08%
EPS Next Y29.66%
EPS Next 2Y21.43%
EPS Next 3Y17.14%
EPS Next 5YN/A
Revenue 1Y (TTM)-5.19%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-21.23%
Revenue Next Year-9.3%
Revenue Next 2Y-1.15%
Revenue Next 3Y2.23%
Revenue Next 5YN/A
EBIT growth 1Y-4.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year78.21%
EBIT Next 3Y84%
EBIT Next 5YN/A
FCF growth 1Y47.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.99%
OCF growth 3Y-50.07%
OCF growth 5Y-39.02%
STRATA SKIN SCIENCES INC / SSKN FAQ
What is the fundamental rating for SSKN stock?
ChartMill assigns a fundamental rating of 1 / 10 to SSKN.
What is the valuation status for SSKN stock?
ChartMill assigns a valuation rating of 0 / 10 to STRATA SKIN SCIENCES INC (SSKN). This can be considered as Overvalued.
How profitable is STRATA SKIN SCIENCES INC (SSKN) stock?
STRATA SKIN SCIENCES INC (SSKN) has a profitability rating of 1 / 10.
Can you provide the financial health for SSKN stock?
The financial health rating of STRATA SKIN SCIENCES INC (SSKN) is 0 / 10.
What is the expected EPS growth for STRATA SKIN SCIENCES INC (SSKN) stock?
The Earnings per Share (EPS) of STRATA SKIN SCIENCES INC (SSKN) is expected to grow by 29.66% in the next year.